Optogenetic Stimulation of the M2 Cortex Reverts Motor Dysfunction in a Mouse Model of Parkinson's Disease

Abstract

Neuromodulation of deep brain structures (deep brain stimulation) is the current surgical procedure for treatment of Parkinson's disease (PD). Less studied is the stimulation of cortical motor areas to treat PD symptoms, although also known to alleviate motor disturbances in PD. We were able to show that optogenetic activation of secondary (M2) motor cortex improves motor functions in dopamine-depleted male mice. The stimulated M2 cortex harbors glutamatergic pyramidal neurons that project to subcortical structures, critically involved in motor control, and makes synaptic contacts with dopaminergic neurons. Strikingly, optogenetic activation of M2 neurons or axons into the dorsomedial striatum increases striatal levels of dopamine and evokes locomotor activity. We found that dopamine neurotransmission sensitizes the locomotor behavior elicited by activation of M2 neurons. Furthermore, combination of intranigral infusion of glutamatergic antagonists and circuit specific optogenetic stimulation revealed that behavioral response depended on the activity of M2 neurons projecting to SNc. Interestingly, repeated M2 stimulation combined with L-DOPA treatment produced an unanticipated improvement in working memory performance, which was absent in control mice under L-DOPA treatment only. Therefore, the M2-basal ganglia circuit is critical for the assembly of the motor and cognitive function, and this study demonstrates a therapeutic mechanism for cortical stimulation in PD that involves recruitment of long-range glutamatergic projection neurons.

FreiPose: A Deep Learning Framework for Precise Animal Motion Capture in 3D Spaces

“…This effect can be quantified via coarse measurements, e.g. rotational behavior, speed, mobile time, mobile episodes, and distance traveled [17,18]. Recently, effects on single body parts have also been started to be investigated via video analysis [19].…”

M2 Cortex-Dorsolateral striatum stimulation reverses motor symptoms and synaptic deficits in Huntington’s Disease

“…Our data reveal that particularly M2-DLS pathway is profoundly compromised in our R6/1 mouse model of HD. The idea to treat brain circuits using optogenetic tools is object to study in many neurological disorders, such as Parkinson (Gradinaru et al, 2009;Kravitz et al, 2010;Magno et al, 2019), stroke (Cheng et al, 2014;Tennant et al, 2017) and psychiatric disorders (Fuchikami et al, 2015). In this line, we aimed to restore circuit function in HD by increasing selected cortico-striatal activity in symptomatic mouse.…”

Contribution of neuronal calcium sensor 1 (Ncs-1) to anxiolytic-like and social behavior mediated by valproate and Gsk3 inhibition

“…Stereotaxic Injections. Stereotaxic injections were performed as previously described 40 . After performing a craniotomy, 1.0 μL of AAV/hSyn-NCS1-EYFP (4 ×10 12 vg/mL), AAV/hSyn-EYFP (4 ×10 12 vg/mL), GFP-Fxr1 (4.4 ×10 12 vg/mL) or GFP (3 ×10 12 vg/mL), was injected per site (anterior-posterior (AP), +2.4 mm; medio-lateral (ML), ±0.5 mm; dorso-ventral (DV), 1.7 mm for dmPFC) using a microinjector at 0.1 μL/min.…”

“…Histology. Histology was performed as previously described 40 . Tissue sections were incubated with a chicken polyclonal antibody against NeuN (1:1,000, Millipore #ABN91, RRID:AB_11212808) and then labelled with a goat anti-chicken Alexa 594 secondary antibody (1:10,000, Thermo #A-11042, RRID:AB_253409).…”